Source MS Society:
A new study will investigate whether early treatment with aggressive disease modifying therapies (DMTs) could benefit people with MS.
The project has received £10 million for clinical trials in the UK and the US. It will last five years and involve 800 people with relapsing MS from the UK.
Fast or slow?
Dr Nikos Evangelou from the University of Nottingham, who is running the trial in the UK, said: “As we diagnose MS, we still don’t know how best to treat it. Some doctors advocate hitting the disease hard to avoid the damage and disability that can develop early, and some suggest going more slowly to avoid potential side effects of the medicine.”
Our James Lind Alliance Priority Setting Partnership asked people with MS what research questions were most important to them. Answering this question is one of the top 10 priorities. Read on.